SCHEDULE 13G/A: Baillie Gifford & Co Discloses 4.05% Stake in Nanobiotix S.A.

Investment adviser Baillie Gifford & Co has reported a 4.05% beneficial ownership stake in Nanobiotix S.A. as of December 31, 2024.

Summary

• Baillie Gifford & Co, an investment adviser based in the United Kingdom, has filed an Amendment No. 5 to Schedule 13G regarding its beneficial ownership in Nanobiotix S.A.
• As of December 31, 2024, Baillie Gifford & Co beneficially owned 1,919,670 shares of Nanobiotix S.A. Common Stock.
• This ownership represents 4.05% of the total class of securities.
• Baillie Gifford & Co holds sole voting power and sole dispositive power over all 1,919,670 shares.
• The filing certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of Nanobiotix S.A.

Sentiment

Score: 7

Explanation: The filing indicates continued institutional confidence from a reputable investment firm, Baillie Gifford & Co, holding a significant stake. While it's a routine disclosure and not a performance report, the maintenance of a substantial position by a major investor is generally a positive signal.

Positives

• A significant institutional investor, Baillie Gifford & Co, maintains a substantial stake in Nanobiotix S.A., indicating continued confidence.
• The filing confirms that the investment is for ordinary course of business purposes, not for control, suggesting a passive, long-term investment perspective.

Future Outlook

This Schedule 13G filing is a disclosure of current beneficial ownership and does not contain forward-looking statements or guidance regarding Nanobiotix S.A.'s future performance or Baillie Gifford & Co's investment strategy beyond the certification that shares are held in the ordinary course of business.

Management Comments

• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11."
• "By signing below I certify that, to the best of my knowledge and belief, the foreign regulatory scheme applicable to Investment Adviser is substantially comparable to the regulatory scheme applicable to the functionally equivalent U.S. institution(s)."

Industry Context

This filing is a routine disclosure of institutional ownership. It indicates that a significant investment adviser, Baillie Gifford & Co, maintains a position in Nanobiotix S.A., a biotechnology company. Such disclosures are common in the investment industry and provide transparency regarding large shareholder positions, which can be a signal of institutional confidence in the company's long-term prospects within the biotech sector.

Comparison to Industry Standards

• As a Schedule 13G filing, this document primarily serves as a regulatory disclosure of beneficial ownership and does not provide financial or operational results for comparison to industry standards. It simply states the ownership percentage of Baillie Gifford & Co in Nanobiotix S.A. (4.05%). Without specific financial or operational data from Nanobiotix S.A. or its peers, a direct comparison of performance or valuation metrics is not possible based solely on this document.

Stakeholder Impact

• Shareholders: Provides transparency on a significant institutional holder's position, potentially influencing investor sentiment.
• Company Management: Awareness of a large, passive institutional investor's stake.

Key Dates

Keywords

Nanobiotix S.A., Baillie Gifford & Co, Schedule 13G, Beneficial Ownership, Common Stock, Investment Adviser, Institutional Investor, SEC Filing